Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01718743 · FLOW

Participant flow

Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma · Source last updated 2025-01-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Beginning 60-180 days post-transplant, participants receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Ixazomib Citrate: Given PO Lenalidomide: Given PO Questionnaire Administration: Ancillary studies
    id
    FG000
    title
    Treatment (Ixazomib Citrate, Lenalidomide)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        7
      type
      Physician Decision
    2. reasons
      1. group Id
        FG000
        num Subjects
        14
      type
      Withdrawal by Subject
    3. reasons
      1. group Id
        FG000
        num Subjects
        22
      type
      Progressive Disease
    4. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Toxicity
    5. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Malignancy
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        64
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        19
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        45
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Participants with the following conditions were excluded from the study: grade 2 or higher peripheral neuropathy; major surgery or radiotherapy within 14 days of starting on the study; central nervous system involvement; treatment with modulators of CYP1A2 and CYP3A enzyme activity; and cardiovascular complications or ongoing systemic infections.
recruitment Details
64 participants were enrolled in the study between December 3, 2012 and May 13, 2015
Complete source fields
groups
  1. description
    Beginning 60-180 days post-transplant, participants receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Ixazomib Citrate: Given PO Lenalidomide: Given PO Questionnaire Administration: Ancillary studies
    id
    FG000
    title
    Treatment (Ixazomib Citrate, Lenalidomide)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        7
      type
      Physician Decision
    2. reasons
      1. group Id
        FG000
        num Subjects
        14
      type
      Withdrawal by Subject
    3. reasons
      1. group Id
        FG000
        num Subjects
        22
      type
      Progressive Disease
    4. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Toxicity
    5. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Malignancy
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        64
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        19
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        45
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Participants with the following conditions were excluded from the study: grade 2 or higher peripheral neuropathy; major surgery or radiotherapy within 14 days of starting on the study; central nervous system involvement; treatment with modulators of CYP1A2 and CYP3A enzyme activity; and cardiovascular complications or ongoing systemic infections.
recruitment Details
64 participants were enrolled in the study between December 3, 2012 and May 13, 2015

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice